Patent · US Expired

Angiogenesis inhibiting thiadiazolyl pyridazine derivatives

US6602873B2 · kind B2 · utility

2Cited by
3References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 24, 2001
Grant dateAug 5, 2003
Priority date
Expiry dateMay 24, 2021

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D417/14
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

This invention concerns compounds of formula the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein R1 is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(C1-6alkyl)amino, Ar1, Ar1—NH—, C3-6cycloalkyl, hydroxymethyl or benzyloxymethyl; R2 and R3 are hydrogen, or taken together may form a bivalent radical of formula —CH═CH—CH═CH—; R4, R5 and R6 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, C1-6alkyloxyC1-6alkyl, C1-6alkylthio, C1-6alkyloxycarbonyl or Het1; or when R4 and R5 are adjacent to each other they may be taken together to form a radical of formula —CH═CH—CH═CH—; A is a bivalent radical of formula NR7, NR7-Alk1-X-, NR7-Alk1-X-Alk2-, O-Alk1-X-, O-Alk1-X-Alk2- or S-Alk1-X-; wherein X is a direct bond, —O—, —S—, C═O, —NR8— or Het2; R7 is hydrogen, C1-6alkyl or Ar2methyl; R8 is hydrogen, C1-6alkyl or Ar2methyl; Alk1 is C1-6alkanediyl; Alk2 is C1-4alkanediyl; Ar1 and Ar2 are optionally substituted phenyl; pheny…

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.